ZYBERNO
Stock Report
Updated Aug 31, 2026

Adicet Bio, Inc. (ACET)

Healthcare • NASDAQ

$8.70

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
Adicet Bio, Inc. (ACET) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-74.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.21x)
Operating Margin (Operational Efficiency):CRITICAL (-1,992.1%)
Return on Capital (Capital Efficiency):CRITICAL (-78.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Adicet Bio, Inc. (ACET) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ACET generated -$91.64M in Owner Earnings. Capital was deployed as follows: $283.00K invested in capital expenditures. Reinvestment rate: 6.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:8.70
Market Cap:$93.49M

Valuation Multiples (3)

P/B Ratio:0.78x
P/S Ratio:17.96x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$72.41M

Price Action & Momentum (3)

Momentum Percentile:28 / 100
% of 52-Week High:49.9%
B. Profitability Assessment

Return Metrics (5)

ROA:-60.9%
Reinvestment Rate:6.0%
Fundamental Growth Rate (g):-4.7%

Margin Analysis (3)

Operating Margin Ttm:-1,992.1%
Net Margin Ttm:-1,901.2%
Ebitda Margin:-1,883.7%

TTM Performance (2)

Operating Margin Ttm:-1,992.1%
Net Margin Ttm:-1,901.2%

Yield Metrics (2)

Earnings Yield:-$244.19
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-39.2%
Latest Earnings Filed:2026-08-05

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-17.5%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.71x
Quick Ratio:6.71x
Cash Ratio:1.84x

Leverage Analysis (3)

Debt To Equity Ttm:0.21x
Debt-to-Equity Ratio:0.21x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,507.58x
Times Interest Earned:-1,507.58

Capital Structure (4)

Working Capital:102,762,000.00
Cash And Cash Equivalents:33,131,000.00
Long Term Debt:$9.40M
Net Debt:-$21.08M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $5.21M
Linear Growth: -17.5%
📊 Click to view full ACET Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$103.71M

Bottom Line Performance (3)

-$98.97M
Income Before Tax:-$98.83M
Ebitda Ttm:-98,065,000.00

Operating Expenses (5)

Operating Expenses:103,708,000.00
R And D Expense:83,826,000.00
Sga Expense:19,882,000.00
Income Tax Expense:$143.00K
Interest Expense:81,000.00

Expense Ratios (3)

R And D To Revenue Percentage:7,176.9%
Sga To Revenue Percentage:1,702.2%
Ebitda Margin:-1,883.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$148.17M
Current Assets:$120.76M
Ppe Net:43,956,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:28,028,000.00
Current Liabilities:18,001,000.00
Long Term Debt:$9.40M
Short Term Debt:$2.66M

Equity & Capital (3)

Equity:$120.14M
Retained Earnings:-$656.30M
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:3,592,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:1,400,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$91.34M-$91.62M

Investment Activities (2)

Investing Cash Flow:$18.88M
Capital Expenditures Ttm:283,000.00

Financing Activities (3)

Financing Cash Flow:-$65.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:5,643,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-20.17
-$20.17
Earnings Per Share Ttm:-$9.21

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.48
Operating Cash Flow Per Share:-$8.86

Book Value & Capital (2)

Book Value Per Share:$11.18
Cash Per Share:3.08

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.03x
Working Capital Turnover Ttm:0.05x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:251.84
Cash Conversion Cycle:-2,249.84
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$91.64M

Damodaran Growth Analysis (2)

Reinvestment Rate:6.0%
Fundamental Growth Rate (g):-4.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-17.5%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-20.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:ACET
Company Name:Adicet Bio, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:10.75M
Shares Outstanding Basic:10.75M
Shares Outstanding Diluted:10.75M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 22:59:02 UTC
Data Timestamp:2026-08-20T02:32:55.574187
Scroll to Top